[HTML][HTML] Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases

J Doroszkiewicz, M Groblewska, B Mroczko - International Journal of …, 2022 - mdpi.com
The degeneration and dysfunction of neurons are key features of neurodegenerative
diseases (NDs). Currently, one of the main challenges facing researchers and clinicians is …

The human gut microbiota in people with amyotrophic lateral sclerosis

K Nicholson, K Bjornevik, G Abu-Ali… - … Lateral Sclerosis and …, 2021 - Taylor & Francis
Objective To characterize the gut microbiota in people with amyotrophic lateral sclerosis
(ALS) relative to controls and to test the hypothesis that butyrate-producing bacteria are less …

Molecular insight in the multifunctional activities of Withaferin A

WV Berghe, L Sabbe, M Kaileh, G Haegeman… - Biochemical …, 2012 - Elsevier
Herbal medicine which involves the use of plants for their medicinal value, dates as far back
as the origin of mankind and demonstrates an array of applications including cardiovascular …

Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis

C Yang, H Wang, T Qiao, B Yang… - Proceedings of the …, 2014 - National Acad Sciences
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease that causes motor neuron
degeneration, progressive motor dysfunction, paralysis, and death. Although multiple …

[HTML][HTML] Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations

A Konopka, DR Whelan, MS Jamali, E Perri… - Molecular …, 2020 - Springer
Background Pathological forms of TAR DNA-binding protein 43 (TDP-43) are present in
motor neurons of almost all amyotrophic lateral sclerosis (ALS) patients, and mutations in …

[HTML][HTML] Emerging therapies and novel targets for TDP-43 proteinopathy in ALS/FTD

LR Hayes, P Kalab - Neurotherapeutics, 2022 - Elsevier
Nuclear clearance and cytoplasmic mislocalization of the essential RNA binding protein,
TDP-43, is a pathologic hallmark of amyotrophic lateral sclerosis, frontotemporal dementia …

Whole-genome sequencing reveals that variants in the interleukin 18 receptor accessory protein 3′ UTR protect against ALS

C Eitan, A Siany, E Barkan, T Olender, KR van Eijk… - Nature …, 2022 - nature.com
The noncoding genome is substantially larger than the protein-coding genome but has been
largely unexplored by genetic association studies. Here, we performed region-based rare …

[HTML][HTML] The peripheral immune system and amyotrophic lateral sclerosis

PA McCombe, JD Lee, TM Woodruff… - Frontiers in …, 2020 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease that is defined by
loss of upper and lower motor neurons, associated with accumulation of protein aggregates …

Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities

P Soares, C Silva, D Chavarria, FSG Silva… - Ageing Research …, 2023 - Elsevier
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of upper and lower
motor neurons (MNs) leading to paralysis and, ultimately, death by respiratory failure 3–5 …

[HTML][HTML] Key role of UBQLN2 in pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia

L Renaud, V Picher-Martel, P Codron… - Acta neuropathologica …, 2019 - Springer
Abstract Ubiquilin-2 (UBQLN2) is a member of the ubiquilin family, actively implicated in the
degradation of misfolded and redundant proteins through the ubiquitin-proteasome system …